Literature DB >> 26803809

Predicting glioblastoma response to bevacizumab through marker profiling?

Tobias Kessler1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26803809      PMCID： PMC4724189          DOI： 10.1093/neuonc/nov320

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  14 in total

1.  MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in high-grade glioma.

Authors:  Emeline Tabouret; Françoise Boudouresque; Patrizia Farina; Maryline Barrié; Céline Bequet; Marc Sanson; Olivier Chinot
Journal:  Neuro Oncol       Date:  2015-08       Impact factor: 12.300

2.  Bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; Erik P Sulman; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-05-22       Impact factor: 91.245

3.  Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.

Authors:  Peter Baumgarten; Anna-Eva Blank; Kea Franz; Elke Hattingen; Maika Dunst; Pia Zeiner; Katharina Hoffmann; Oliver Bähr; Lisa Mäder; Benjamin Goeppert; Marcia Machein; Volker Seifert; Joachim P Steinbach; Karl H Plate; Patrick N Harter; Michel Mittelbronn
Journal:  Neuro Oncol       Date:  2015-11-30       Impact factor: 12.300

4.  Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.

Authors:  Thomas Sandmann; Richard Bourgon; Josep Garcia; Congfen Li; Timothy Cloughesy; Olivier L Chinot; Wolfgang Wick; Ryo Nishikawa; Warren Mason; Roger Henriksson; Frank Saran; Albert Lai; Nicola Moore; Samir Kharbanda; Franklin Peale; Priti Hegde; Lauren E Abrey; Heidi S Phillips; Carlos Bais
Journal:  J Clin Oncol       Date:  2015-06-29       Impact factor: 44.544

5.  Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma.

Authors:  Emeline Tabouret; Françoise Boudouresque; Maryline Barrie; Mona Matta; Celine Boucard; Anderson Loundou; Antoine Carpentier; Marc Sanson; Philippe Metellus; Dominique Figarella-Branger; L'houcine Ouafik; Olivier Chinot
Journal:  Neuro Oncol       Date:  2013-12-09       Impact factor: 12.300

6.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

Authors:  Olivier L Chinot; Wolfgang Wick; Warren Mason; Roger Henriksson; Frank Saran; Ryo Nishikawa; Antoine F Carpentier; Khe Hoang-Xuan; Petr Kavan; Dana Cernea; Alba A Brandes; Magalie Hilton; Lauren Abrey; Timothy Cloughesy
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

7.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Authors:  Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

8.  Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth.

Authors:  Petra Hamerlik; Justin D Lathia; Rikke Rasmussen; Qiulian Wu; Jirina Bartkova; MyungHee Lee; Pavel Moudry; Jiri Bartek; Walter Fischer; Jiri Lukas; Jeremy N Rich; Jiri Bartek
Journal:  J Exp Med       Date:  2012-03-05       Impact factor: 14.307

9.  Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial.

Authors:  N Beije; J Kraan; W Taal; B van der Holt; H M Oosterkamp; A M Walenkamp; L Beerepoot; M Hanse; M E van Linde; A Otten; R M Vernhout; F Y F de Vos; J W Gratama; S Sleijfer; M J van den Bent
Journal:  Br J Cancer       Date:  2015-06-04       Impact factor: 7.640

10.  Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.

Authors:  Tobias Kessler; Felix Sahm; Jonas Blaes; Matthias Osswald; Petra Rübmann; David Milford; Severino Urban; Leonie Jestaedt; Sabine Heiland; Martin Bendszus; Anne Hertenstein; Philipp-Niclas Pfenning; Carmen Ruiz de Almodóvar; Antje Wick; Frank Winkler; Andreas von Deimling; Michael Platten; Wolfgang Wick; Markus Weiler
Journal:  Oncotarget       Date:  2015-10-13
View more
  1 in total

1.  Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of neuropathology in the management of progressive glioblastoma in adults.

Authors:  Abigail L Goodman; José E Velázquez Vega; Chad Glenn; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2022-06-01       Impact factor: 4.130
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.